Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: A historical perspective

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Biopolymers

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry, History

• Identifiers
  DOI 10.1002/bip.20802PMID 17610261
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.

  2009cited by this paper
• Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin.

  2009cited by this paper
• Design and synthesis of potent in vivo antagonists of oxytocin.

  2009cited by this paper
• The Role of the Merrifield Solid Phase Method in the Discovery and Exploration of a New Class of Selective Vasopressin Hypotensive Agonists

  2007cited by this paper
• Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.

  2007cited by this paper
• Design and synthesis of potent, highly selective vasopressin hypotensive agonists

  2006cited by this paper
• Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban

  2005cited by this paper
• Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.

  2004cited by this paper
• Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue

  2003cited by this paper
• 124 years of publishing original and primary chemical research: 135,149 publications, 573,453 pages, and a century of excellence.

  2003cited by this paper
• Design of Oxytocin Antagonists, which are more Selective than Atosiban

  2001cited by this paper
• Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays

  2000cited by this paper
• Synthesis and structure–activity investigation of novel vasopressin hypotensive peptide agonists

  1999cited by this paper
• Discovery and design of novel vasopressin hypotensive peptide agonists.

  1999cited by this paper
• Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors

  1998cited by this paper
• Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors.

  1997cited by this paper
• Position Three in Vasopressin Antagonist Tolerates Conformationally Restricted and Aromatic Amino Acid Substitutions: A Striking Contrast with Vasopressin Agonists

  1997cited by this paper
• Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.

  1996cited by this paper
• An exploration of the effects of L‐ and D‐tetrahydroisoquinoline‐3‐carboxylic acid substitutions at positions 2,3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin

  1995cited by this paper
• Characterization of a novel, linear radioiodinated vasopressin antagonist: an excellent radioligand for vasopressin V1a receptors.

  1995cited by this paper
• Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.

  1992cited by this paper
• A radioiodinated linear vasopressin antagonist: A ligand with high affinity and specificity for V1a receptors

  1991cited by this paper
• Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.

  1990cited by this paper
• Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.

  1989cited by this paper
• Discovery, development, and some uses of vasopressin and oxytocin antagonists.

  1989cited by this paper
• Potent V2 vasopressin antagonists with structural changes at their C-terminals.

  1988cited by this paper
• 125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand.

  1988cited by this paper
• 125I‐d(CH2)5[Tyr(Me)2,Tyr(NH2)9]AVP: Iodination and binding characteristics of a vasopressin receptor ligand

  1988cited by this paper
• No requirement of cyclic conformation of antagonists in binding to vasopressin receptors

  1987cited by this paper
• Carboxy terminus of vasopressin required for activity but not binding

  1984cited by this paper
• Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4.

  1984cited by this paper
• Design of more potent and selective antagonists of the antidiuretic responses to arginine-vasopressin devoid of antidiuretic agonism.

  1982cited by this paper
• Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.

  1982cited by this paper
• Design of potent and selective antagonists of the vasopressor responses to arginine-vasopressin.

  1982cited by this paper
• Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone.

  1981cited by this paper
• Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin.

  1981cited by this paper
• [1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin.

  1980cited by this paper
• The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin.

  1980cited by this paper
• Synthetic antagonists of in vivo responses by the rat uterus to oxytocin.

  1979cited by this paper
• [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),4-valine,-8-D-arginine]vasopressin, a potent and selective inhibitor of the vasopressor response to arginine-vasopressin.

  1978cited by this paper
• Design of potent antagonists of the vasopressor response to arginine-vasopressin.

  1978cited by this paper
• [1-deaminopenicillamine,4-valine]-8-D-arginine-vasopressin, a highly potent inhibitor of the vasopressor response to arginine-vasopressin.

  1977cited by this paper
• Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic selectivity.

  1977cited by this paper
• Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-oxytocin).

  1976cited by this paper
• Structural changes in the arginine vasopressin molecule that prolong its antidiuretic action.

  1974cited by this paper
• Structural changes in the arginine vasopressin molecule that enhance antidiuretic activity and specificity.

  1974cited by this paper
• Solid phase synthesis of (1-deamino,4-valine)-8-D-arginine-vasopressin (DVDAVP), a highly potent and specific antidiuretic agent possessing protracted effects.

  1973cited by this paper
• Solid phase synthesis of [4-proline]oxytocin, [4-proline]mesotocin, [4-proline]glumitocin, and [4-lysine]mesotocin.

  1971cited by this paper
• Solid-phase synthesis of (4-threonine)-oxytocin. A more potent and specific oxytocic agent than oxytocin.

  1970cited by this paper
• 4-Threonine-Oxytocin: A More Active and Specific Oxytocic Agent than Oxytocin

  1970cited by this paper
• Elasmobranch oxytocin-like principles: comparisons with synthetic glumitocin.

  1969cited by this paper
• 4-Proline analogues of neurohypophysial hormones: hypothetical intermediates in peptide evolution.

  1969cited by this paper
• Solid phase synthesis and some pharmacological properties of 8-glutamine-oxytocin: a possible intermediate in the evolution of the neurohypophysial hormones

  1969cited by this paper
• Solid-phase syntheis and some pharmacological properties of [8-phenylalanine]-oxytocin.

  1969cited by this paper
• The synthesis of deamino-oxytocin by the solid phase method.

  1968cited by this paper
• Solid phase synthesis and some pharmacoogical properties of 4-Ser-8-Gln-Oxytocin (Glumitocin)

  1968cited by this paper
• The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15.

  1968cited by this paper
• Basic Pharmacological Properties of Synthetic Analogues and Homologues of the Neurohypophysial Hormones

  1968cited by this paper
• Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin.

  1968cited by this paper
• 1-Mercaptoacetic Acid-4-β-alanine-oxytocin*

  1967cited by this paper
• 4-β-Alanine-oxytocin: An Oxytocin Analog Containing a Twenty-one-membered Disulfide Ring*

  1965cited by this paper
• 6-Hemi-D-cystine-oxytocin, a diastereoisomer of the posterior pituitary hormone oxytocin.

  1965cited by this paper
• Solid phase peptide synthesis. I. the synthesis of a tetrapeptide

  1963cited by this paper
• The Synthesis of Oxytocin1

  1954cited by this paper
• A SYNTHETIC PREPARATION POSSESSING BIOLOGICAL PROPERTIES ASSOCIATED WITH ARGININEVASOPRESSIN

  1954cited by this paper

• Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides

  2022cites this paper
• Six Decades of History of Hypertension Research at the University of Toledo: Highlighting Pioneering Contributions in Biochemistry, Genetics, and Host-Microbiota Interactions

  2022cites this paper
• 3-Nitro-2-pyridinesulfenyl-mediated solid-phase disulfide ligation in the synthesis of disulfide bond-containing cyclic peptides.

  2015cites this paper
• Segregation of calcium signalling mechanisms in magnocellular neurones and terminals.

  2012cites this paper
• Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

  2012cites this paper
• REVIEW: Oxytocin: Crossing the Bridge between Basic Science and Pharmacotherapy

  2010cites this paper
• Preliminary Analysis of Vital Proteins of the Human Respiratory Syncytial Virus

  2010influential citation
• Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

  2008cites this paper
• Bruce Merrifield and solid‐phase peptide synthesis: A historical assessment

  2007cites this paper